Trial sites conducting Covaxin study say the company has given them an indicative deadline of 31 December to complete the recruitment of volunteers, but company denies claim.
Researchers, however, said evaluation of safety outcomes required extensive phase 3 clinical trials of the Covid vaccine developed through partnership between ICMR & Bharat Biotech.
Govt had sought additional data on the vaccine candidates of companies seeking emergency use authorisation. So far, just one company has submitted this information.
Bharat Biotech has already produced about 10 million doses of Covaxin shot, ahead of anticipated roll out next year. But task of supplying it seems daunting.
The applications of Bharat Biotech and Serum Institute of India are under consideration, while that of the Indian arm of Pfizer has not yet been taken up.
The Ambassadors and High Commissioners visited the facilities of the major pharma companies, which are involved in the manufacturing of Covid vaccine candidate, Covaxin.
3 firms have applied for emergency use approval, but no clarity yet on if people will get to choose a vaccine, or what the state’s role in procurement will be.
The move comes over a month after the MEA briefed over 190 heads of diplomatic missions and representatives of leading international organisations on Covid-19 related issues.
We need to give credit to our attention-starved scientists for their true achievements. Perhaps a good way to start would be to not mix science with religion.
The 125 APAs include 86 Unilateral APAs (UAPAs) and 39 Bilateral APAs (BAPAs). The total number of APAs since the start of the APA programme has risen to 641, with 506 UAPAs and 135 BAPAs.
COMMENTS